newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Announces Equity Research Update by Alliance Global Partners

  • Alliance Global Partners published an updated equity research report on IGC Pharma on February 10, 2026.
  • The report reiterates a Buy rating with a price target of $3.00 per share.
  • IGC Pharma disclaims endorsement or accuracy of the analyst report \& assumes no obligation to update or correct the information.
  • IGC Pharma is a clinical-stage biotechnology company using AI to develop treatments for Alzheimer's \& metabolic disorders.
  • Lead asset IGC-AD1 is a cannabinoid-based therapy currently in Phase 2 CALMA trial for agitation in Alzheimer's dementia.
  • The company's pipeline includes TGR-63 targeting amyloid plaques, plus early-stage programs focused on neurodegeneration, tau proteins, \& metabolic dysfunctions.
  • Forward-looking statements in the release are subject to risks including potential failure to commercialize products, lack of regulatory approval, unfavorable economic conditions, FDA positions on cannabis products, \& AI algorithm performance issues.
  • IGC Pharma references its 2025 Form 10-K filed with the SEC \& assumes no obligation to update forward-looking statements based on new information.